Founded as a spinoff of the Wyss Center in Geneva, Clee Medical is developing technology that enhances neurosurgical procedures through advanced imaging and AI-driven guidance. The startup has been awarded CHF 150,000 by Venture Kick, after winning the third stage of the program.

作为日内瓦Wyss中心的分支创立的Clee Medical公司，正在开发通过先进成像和人工智能引导来提升神经外科手术的技术。该初创公司在此项目第三阶段获胜后，已获得Venture Kick颁发的15万瑞士法郎奖金。

Current neurosurgical procedures face significant hurdles due to limitations in precision imaging and real-time surgical guidance. These challenges not only affect surgical efficiency but also restrict patient outcomes and slow the integration of innovative neuro-technologies.

当前的神经外科手术由于精确成像和实时手术引导的局限性而面临重大障碍。这些挑战不仅影响手术效率，还限制了患者的治疗效果，并减缓了创新神经技术的整合。

Geneva-based startup,

总部位于日内瓦的初创公司，

Clee Medical

克利医疗

addresses these critical challenge by developing innovative imaging and sensing technology and AI-driven navigation technology that delivers ultra-high-resolution, real-time visualization of the brain during surgery, without the need for contrast agents or radiation. Offering 300,000 more voxels per unit volume than MRI, Clee’s technology integrates with existing neurosurgical equipment and can be easily incorporated into current surgical routines..

通过开发创新的成像和传感技术以及人工智能驱动的导航技术，解决了这些关键挑战，在手术过程中提供超高分辨率、实时的大脑可视化，无需使用造影剂或辐射。与MRI相比，Clee的技术每单位体积提供多30万个体素，可与现有的神经外科设备集成，并能轻松融入当前的手术流程。

Clee Medical was co-founded by Matt Lapinski, an accomplished entrepreneur with over a decade of success in Boston’s dynamic medical device industry, and Dr. Abed Hammoud, a veteran innovator with 30+ years of leadership experience in stereotactic neurosurgery and technology ventures. Targeting a global market valued at CHF 2.2 billion, Clee Medical is poised to redefine stereotactic and functional neurosurgery with a new approach that has potential to accelerate the adoption of next generation therapies, improve patient outcomes, and increase surgical capacity..

Clee Medical 由资深企业家 Matt Lapinski 和 Abed Hammoud 博士共同创立。Matt Lapinski 在波士顿充满活力的医疗设备行业拥有十多年的成功经验，而 Abed Hammoud 博士则是立体定向神经外科和技术领域的创新者，拥有 30 多年的领导经验。Clee Medical 致力于开发价值 22 亿瑞士法郎的全球市场，通过一种全新方法重新定义立体定向和功能神经外科，该方法有望加速下一代疗法的采用、改善患者预后并提升手术能力。

With prestigious medical centers as key clients, the company’s technology promises unprecedented accuracy, reduced surgical risk, increased operating capacity, and broader treatment possibilities. The obtained

凭借知名医疗机构作为关键客户，该公司的技术承诺提供前所未有的精确度、降低手术风险、增加手术能力以及更广泛的治疗可能性。所获得的

Venture Kick

风险投资启动

funding will enable Clee Medical to strengthen collaborations with leading neurosurgeons and institutions, expedite early adopter engagement, and swiftly advance toward a first-in-human clinical trial milestone.

资金将使Clee Medical能够加强与领先的神经外科医生和机构的合作，加快早期采用者的参与，并迅速朝着首次人体临床试验的里程碑迈进。

“The Venture Kick process has represented a substantial part of our journey, providing funding, strategic guidance, and access to an incredible network of entrepreneurs and experts,” commented Matthew Lapinski, CEO and Co-Founder of Clee Medical. “We are truly grateful for the opportunity and support that have helped us refine our vision and accelerate our impact.

“Venture Kick 过程代表了我们旅程的重要部分，提供了资金、战略指导，并让我们接触到一个令人难以置信的企业家和专家网络，”Clee Medical 首席执行官兼联合创始人马修·拉平斯基评论道。“我们非常感激所获得的机会和支持，帮助我们完善愿景并加速我们的影响力。”

We are excited to continue and apply our learnings from the Venture Kick process to improve minimally invasive brain surgery worldwide!”.

我们很高兴能够继续并运用从Venture Kick流程中学到的知识，推动全球微创脑外科手术的进步！

(Press release/RAN)

（新闻稿/随机接入网络）

Image: Clee Medical's Co-Founders CEO Matthew Lapinski and CTO Abed Hammoud

图片：Clee Medical的联合创始人兼首席执行官马修·拉宾斯基和首席技术官阿贝德·哈穆德

Never miss a deadline again

再也不会错过截止日期了

Start alarms for award deadlines

启动奖项截止日期的提醒警报

Receive tailor made mails with news about your awards

接收关于您的奖项的定制邮件新闻

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送